{"disease":{"id":"multiple-myeloma-2-prior-therapies","name":"multiple myeloma 2 prior therapies"},"drugs":{"marketed":[{"drug_id":"chembl-chembl3545131","indication_name":"Multiple Myeloma (≥2 prior therapies)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISATUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 20 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 21 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 22 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 23 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 24 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 25 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 26 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 27 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 28 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 29 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 32 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 42 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 52 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 62 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 72 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 82 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 92 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 102 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}